Literature DB >> 23472246

The role of hepatic expression of STAT1, SOCS3 and PIAS1 in the response of chronic hepatitis C patients to therapy.

Sherif El-Saadany, Dina H Ziada, Hanan El Bassat, Wael Farrag, Hesham El-Serogy, Manal Eid, Manal Abdallah, Medhat Ghazy, Hoda A Salem.   

Abstract

BACKGROUND: The underlying mechanisms of hepatitis C virus (HCV) resistance to treatment are unknown. Signal transducers and activators of transcription (STAT) proteins play a critical role in antiviral defense.
OBJECTIVE: To explore some of the mechanisms of HCV resistance to interferon, the expression of STAT1 and its negative regulators, protein inhibitor of activated STAT (PIAS1) and suppressor of cytokine signalling (SOCS3), in liver tissues of both inteferon responders and nonresponders in chronic HCV patients.
METHODS: Sixty patients were divided into the following groups: group 1a comprised 38 treatment-responder chronic HCV patients; group 1b consisted of 22 treatment-nonresponder chronic HCV patients; and group 2 consisted of six control subjects. Liver biopsies were examined for histological scoring; STAT1, SOCS3 and PIAS1 expression was analyzed using Western blotting methods.
RESULTS: STAT1 expression in the liver tissue of patients in group 1 was significantly increased compared with group 2 patients (P=0.001), while no significant difference in expression was observed between group 1a and group 1b patients (P=0.747). However, phosphorylated STAT1 protein was expressed at a significantly higher level in liver tissue of patients in group 1a compared with patients in group 1b (P=0.001). Western blot analysis of PIAS1 and SOCS3 protein expression in liver tissues from groups 1 and 2 revealed significantly increased expression in group 1 compared with group 2 (P=0.001). In addition, PIAS1 and SOCS3 protein expression was significantly higher in the liver tissues of patients in group 1b compared with patients in group 1a.
CONCLUSION: Levels of STAT1 and⁄or the protein expression of its negative regulators, PIAS1 and SOCS3, may be a good predictor of response to therapy. These could be used as biomarkers that are easily detected by Western blotting or immunostaining during standard histopathological liver biopsy analysis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23472246      PMCID: PMC3731121          DOI: 10.1155/2013/562765

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  22 in total

1.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

Review 2.  Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.

Authors:  Alfredo Alberti; Nathan Clumeck; Simon Collins; Wolfram Gerlich; Jens Lundgren; Giorgio Palù; Peter Reiss; Rodolphe Thiebaut; Ola Weiland; Yazdan Yazdanpanah; Stefan Zeuzem
Journal:  J Hepatol       Date:  2005-05       Impact factor: 25.083

3.  Predictive value of the phosphorylation of signal transducers and activators of transcription in the outcome of interferon therapy for chronic hepatitis C.

Authors:  Hisamitsu Miyaaki; Tatsuki Ichikawa; Kazuhiko Nakao; Shigeyuki Takeshita; Hidetaka Shibata; Eisuke Ozawa; Motohisa Akiyama; Satoshi Miuma; Katsumi Eguchi
Journal:  Intervirology       Date:  2009-03-04       Impact factor: 1.763

4.  Dynamics of GB virus C viremia early after orthotopic liver transplantation indicates extrahepatic tissues as the predominant site of GB virus C replication.

Authors:  T Berg; A R Müller; K P Platz; M Höhne; W O Bechstein; U Hopf; B Wiedenmann; P Neuhaus; E Schreier
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

5.  Distinct roles of the NH2- and COOH-terminal domains of the protein inhibitor of activated signal transducer and activator of transcription (STAT) 1 (PIAS1) in cytokine-induced PIAS1-Stat1 interaction.

Authors:  J Liao; Y Fu; K Shuai
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

6.  STAT3 complements defects in an interferon-resistant cell line: evidence for an essential role for STAT3 in interferon signaling and biological activities.

Authors:  C H Yang; A Murti; L M Pfeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

7.  Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4.

Authors:  A el-Zayadi; P Simmonds; H Dabbous; L Prescott; O Selim; A Ahdy
Journal:  J Viral Hepat       Date:  1996-09       Impact factor: 3.728

8.  Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

Authors:  Bart J Veldt; E Jenny Heathcote; Heiner Wedemeyer; Juerg Reichen; W Peter Hofmann; Stefan Zeuzem; Michael P Manns; Bettina E Hansen; Solko W Schalm; Harry L A Janssen
Journal:  Ann Intern Med       Date:  2007-11-20       Impact factor: 25.391

9.  A screening method for identifying disruptions in interferon signaling reveals HCV NS3/4a disrupts Stat-1 phosphorylation.

Authors:  Karla J Helbig; Evelyn Yip; Erin M McCartney; Nicholas S Eyre; Michael R Beard
Journal:  Antiviral Res       Date:  2007-12-26       Impact factor: 5.970

10.  Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance.

Authors:  Haizhen Zhu; David R Nelson; James M Crawford; Chen Liu
Journal:  J Interferon Cytokine Res       Date:  2005-09       Impact factor: 2.607

View more
  7 in total

Review 1.  SOCS3 revisited: a broad regulator of disease, now ready for therapeutic use?

Authors:  R Mahony; S Ahmed; C Diskin; N J Stevenson
Journal:  Cell Mol Life Sci       Date:  2016-05-02       Impact factor: 9.261

2.  Hepatitis C virus induces a prediabetic state by directly impairing hepatic glucose metabolism in mice.

Authors:  Hervé Lerat; Mohamed Rabah Imache; Jacqueline Polyte; Aurore Gaudin; Marion Mercey; Flora Donati; Camille Baudesson; Martin R Higgs; Alexandre Picard; Christophe Magnan; Fabienne Foufelle; Jean-Michel Pawlotsky
Journal:  J Biol Chem       Date:  2017-05-30       Impact factor: 5.157

Review 3.  The IFN-λ4 Conundrum: When a Good Interferon Goes Bad.

Authors:  Olusegun O Onabajo; Brian Muchmore; Ludmila Prokunina-Olsson
Journal:  J Interferon Cytokine Res       Date:  2019-06-26       Impact factor: 2.607

4.  GRIM-19 Restricts HCV Replication by Attenuating Intracellular Lipid Accumulation.

Authors:  Jung-Hee Kim; Pil S Sung; Eun B Lee; Wonhee Hur; Dong J Park; Eui-Cheol Shin; Marc P Windisch; Seung K Yoon
Journal:  Front Microbiol       Date:  2017-04-11       Impact factor: 5.640

Review 5.  SOCS Proteins Participate in the Regulation of Innate Immune Response Caused by Viruses.

Authors:  Shanzhi Huang; Ke Liu; Anchun Cheng; Mingshu Wang; Min Cui; Juan Huang; Dekang Zhu; Shun Chen; Mafeng Liu; Xinxin Zhao; Yin Wu; Qiao Yang; Shaqiu Zhang; Xumin Ou; Sai Mao; Qun Gao; Yanling Yu; Bin Tian; Yunya Liu; Ling Zhang; Zhongqiong Yin; Bo Jing; Xiaoyue Chen; Renyong Jia
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

6.  Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses.

Authors:  Ping Meng; Suxian Zhao; Xuemin Niu; Na Fu; Shanshan Su; Rongqi Wang; Yuguo Zhang; Liang Qiao; Yuemin Nan
Journal:  Int J Mol Sci       Date:  2016-07-15       Impact factor: 5.923

7.  HCV infection causes cirrhosis in human by step-wise regulation of host genes involved in cellular functioning and defense during fibrosis: Identification of bio-markers.

Authors:  Bushra Ijaz; Waqar Ahmad; Trina Das; Khadija Shabbiri; Tayyab Husnain; Sajida Hassan
Journal:  Genes Dis       Date:  2019-05-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.